Xtant Medical Holdings, Inc. focuses on surgical solutions for spinal and other orthopedic conditions. I follow XTNT because the company sits at the intersection of two significant healthcare areas: regenerative medicine through biologics that aid bone healing and spinal implant hardware. Though smaller than major industry players, Xtant has aimed to stand out with a vertically integrated biologics platform and a wide range of products for orthopedic spine surgeons and neurosurgeons.
Xtant Medical Holdings, Inc. originated from what was once known as Bacterin International Holdings, Inc. It is incorporated in Delaware, with its main offices in Belgrade, Montana. The common stock trades on the NYSE American exchange under the symbol XTNT. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company develops, manufactures, and markets regenerative medicine products and medical devices for both domestic and international markets. Its offerings address the needs of orthopedic and neurological surgeons, including orthobiologics to support bone healing, implants and instrumentation for spinal conditions, and tissue grafts for orthopedic, cranial, and foot and ankle procedures.
Xtant’s orthobiologics lineup features items such as OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix designed to support bone formation; along with 3Demin, OsteoFactor Pro, OsteoVive Plus, and the nanOss line of synthetic bone-graft substitutes. On the hardware side, it provides spinal implant systems for cervical, thoracolumbar, sacroiliac joint, and interbody categories, plus related instrumentation.
Revenue comes mainly from selling biologics and spinal implant products to hospitals, surgical centers, and surgeons. In the United States, Xtant markets through a network of independent commissioned agents and stocking distributors, backed by direct employees. It also runs a national accounts program for access to integrated delivery networks and group purchasing organizations. While the U.S. remains the primary market, the company sells internationally via distributors and direct representatives.
Recent efforts have centered on becoming a vertically integrated biologics manufacturer, handling stem cell, growth factor, amniotic tissue, and synthetic products in-house to better control the supply chain, quality, and margins.
Investors track XTNT for several structural reasons. The spinal and orthopedic surgery market benefits from an aging population and higher rates of degenerative spinal issues. Orthobiologics form a growth segment as surgeons pair bone-graft materials with hardware to enhance fusion results. Xtant’s positioning rests on its broad, vertically integrated biologics portfolio and its dual focus on biologics plus hardware, enabling complementary offerings in a single procedure. New product launches and distribution agreements have helped expand into areas like hemostatic products.
Investing in XTNT involves notable risks. As a small-cap medical device firm, Xtant competes with larger, better-funded rivals that have stronger marketing and broader lines. Revenue can shift with changes in government and private payer reimbursement policies that influence hospital and surgeon purchasing decisions. Operationally, results have varied over time amid investments in new products and distribution. Additional factors include customer and channel concentration, supply-chain dependencies, and regulatory demands for tissue-based and device products. The company also reviews divestitures and strategic moves that can alter its mix and results.
In my research, I often rely on Tickeron’s AI Screener to quickly filter stocks using technical indicators, fundamentals, and industry filters. This helps me spot ideas that fit my own strategies without spending hours on manual reviews.
Xtant Medical Holdings, Inc. operates as a specialized medical technology company that pairs regenerative biologics with spinal implant systems for orthopedic and neurological surgeons. Its vertically integrated manufacturing, broad portfolio, and position in a sizable healthcare market set it apart among small-cap device companies. At the same time, its scale, reimbursement exposure, and industry competition remain important factors. For those looking at medical device and regenerative medicine exposure, XTNT provides a targeted, higher-risk avenue into that space.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XTNT's RSI Oscillator exited the oversold zone, 19 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for XTNT just turned positive on November 04, 2026. Looking at past instances where XTNT's MACD turned positive, the stock continued to rise in 43 of 48 cases over the following month. The odds of a continued upward trend are 90%.
Following a +7.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where XTNT advanced for three days, in 195 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
XTNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XTNT as a result. In 78 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XTNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for XTNT entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.015) is normal, around the industry mean (4.142). P/E Ratio (-3.618) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.426) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. XTNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XTNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of surgical products
Industry MedicalNursingServices